✦ LIBER ✦

Maximizing the Benefit of Pharmacotherapy in Parkinson's Disease

✍ Scribed by Richard C. Berchou

Book ID: 115047902
Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 56 KB
Volume: 20
Category: Article
ISSN: 0277-0008
DOI: 10.1592/phco.20.2.33s.34632

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Maximizing the Benefit: Risk Ratio of Le

Maximizing the Benefit: Risk Ratio of Levodopa Therapy in Parkinson's Disease

✍ Mildred D. Gottwald 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB

Pharmacotherapy of Parkinson’s disease i

Pharmacotherapy of Parkinson’s disease in Germany

✍ J. C. Möller; Y. Körner; R. C. Dodel; C. Meindorfner; K. Stiasny-Kolster; A. Spo 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 368 KB

Contemporary Issues in the Pharmacothera

Contemporary Issues in the Pharmacotherapy of Parkinson's Disease

📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 26 KB

Contemporary Issues in Pharmacotherapy o

Contemporary Issues in Pharmacotherapy of Parkinson's Disease

✍ Richard C. Berchou 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 16 KB

Sleep benefit in parkinson's disease

✍ Dr. Marcelo Merello; Andrew Hughes; Carlo Colosimo; Marion Hoffman; Sergio Stark 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB

## Abstract Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% r

Rasagiline in the pharmacotherapy of Par

Rasagiline in the pharmacotherapy of Parkinson’s disease – a review

✍ Rascol, Olivier 📂 Article 📅 2005 🏛 Informa plc 🌐 English ⚖ 246 KB